Hani Goodarzi

In this engaging discussion, Nima Alidoust, CEO of Vevo Therapeutics, and Patrick Hsu, CEO of the Arc Institute, dive into the revolutionary Tahoe-100M dataset that is reshaping drug discovery. They explore the fascinating potential of virtual cell models and AI in understanding disease behaviors at a cellular level. The conversation highlights challenges in data collection and the critical need for high-quality datasets in biomedical research. They also discuss the importance of open-sourcing data to foster collaboration and innovation in the biotech field.

In this enlightening discussion, Hani Goodarzi, a core investigator at the ARC Institute, shares insights on the Virtual Cell Atlas, a groundbreaking initiative that aggregates single-cell data. Joining him are Gilad Almogy, CEO of Ultima Genomics, who highlights their cost-effective sequencing technology, and Serge Saxonov, CEO of 10x Genomics, explaining how scalable sequencing enables extensive data generation. Together, they explore how this innovative platform aims to revolutionize drug discovery, offering models that predict cellular responses and enhance understanding of disease mechanisms.

Biomedical researcher Hani Goodarzi discusses the discovery of a new class of RNAs for early cancer detection. He explores the challenges of spotting cancer cells in a healthy body and the potential of using AI tools for precise detection through routine blood work. The discussion sheds light on how cancer cells manipulate genomic machinery to create oncarnas, revolutionizing cancer detection and personalized care.